Cannabis use among Canadian Armed Forces members and Veterans: discussion from a 2017 CIMVHR Forum working group

[1]  G. M. Allan,et al.  Simplified guideline for prescribing medical cannabinoids in primary care. , 2018, Canadian family physician Medecin de famille canadien.

[2]  D. Kansagara,et al.  Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder , 2017, Annals of Internal Medicine.

[3]  W. van den Brink,et al.  Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations , 2017, American journal of public health.

[4]  E. Elbogen,et al.  Cannabis use disorder and suicide attempts in Iraq/Afghanistan-era veterans. , 2017, Journal of psychiatric research.

[5]  I. Galatzer-Levy,et al.  Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review , 2017, Depression and anxiety.

[6]  D. Hien,et al.  Impact of Cannabis Use on Treatment Outcomes among Adults Receiving Cognitive-Behavioral Treatment for PTSD and Substance Use Disorders , 2017, Journal of clinical medicine.

[7]  D. D’Souza,et al.  A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. , 2016, The Journal of clinical psychiatry.

[8]  R. Rosenheck,et al.  Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. , 2015, The Journal of clinical psychiatry.

[9]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[10]  R. Jetly,et al.  The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study , 2015, Psychoneuroendocrinology.

[11]  C. Cameron,et al.  Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder–Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications , 2014, Journal of clinical psychopharmacology.

[12]  A. Neumeister.  THE ENDOCANNABINOID SYSTEM PROVIDES AN AVENUE FOR EVIDENCE‐BASED TREATMENT DEVELOPMENT FOR PTSD , 2013, Depression and anxiety.

[13]  J. Rehm,et al.  Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A Narrative Review of Evidence and Recommendations , 2011, Canadian journal of public health = Revue canadienne de sante publique.

[14]  George A Fraser,et al.  The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) , 2009, CNS neuroscience & therapeutics.

[15]  H. Westenberg,et al.  Pharmacotherapeutic Treatment of Nightmares and Insomnia in Posttraumatic Stress Disorder , 2006, Annals of the New York Academy of Sciences.